Changeflow GovPing Pharma & Drug Safety Bipartite molecules treating neurodegenerative ...
Routine Notice Added Final

Bipartite molecules treating neurodegenerative diseases

Favicon for changeflow.com USPTO Patent Grants - Peptides (C07K)
Published
Detected
Email

Summary

USPTO granted Patent US12590130B2 to Academia Sinica for bipartite molecules comprising a peptide affinity moiety and charged moieties for treating neurodegenerative diseases associated with abnormal protein aggregates. The patent contains 6 claims and was granted March 31, 2026, with original filing date November 27, 2020. No compliance deadlines are associated with this patent grant.

Published by USPTO on changeflow.com . Detected, standardized, and enriched by GovPing. Review our methodology and editorial standards .

What changed

USPTO granted Patent US12590130B2 to Academia Sinica (Taiwan) covering bipartite molecules with peptide affinity and charged moieties designed to reduce abnormal protein aggregate formation for treating neurodegenerative diseases. The patent names 8 inventors and includes 6 claims. This is a standard patent grant notification informing the public of newly issued patent rights.

Pharmaceutical companies and biotechnology firms developing treatments for neurodegenerative diseases should review this patent to assess potential licensing needs orFreedom-to-operate implications for competing therapeutic approaches. Drug manufacturers conducting research in this space may need to consider patent clearance before commercializing related products.

Archived snapshot

Mar 31, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← USPTO Patent Grants

Bipartite molecules and uses thereof in treating diseases associated with abnormal protein aggregates

Grant US12590130B2 Kind: B2 Mar 31, 2026

Assignee

Academia Sinica

Inventors

Benjamin Pang-Hsien Tu, Rita Py Chen, Joseph Jen-Tse Huang, Yijuang Chern, Yu-Song Jang, Xiang-Me Lai, Tai-Yan Liao, Te-Hsien Kung

Abstract

Bipartite molecules comprising a peptide affinity moiety and at least one charged moiety and uses thereof in reducing formation of abnormal protein aggregate and treating diseases associated with such abnormal protein aggregate, including neurodegenerative disease characterized by formation of protein aggregates.

CPC Classifications

C07K 14/4711 C07K 14/4703 C07K 2319/00 A61K 38/00

Filing Date

2020-11-27

Application No.

17105858

Claims

6

View original document →

Named provisions

Abstract

Get daily alerts for USPTO Patent Grants - Peptides (C07K)

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from USPTO.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
USPTO
Published
March 31st, 2026
Instrument
Notice
Legal weight
Binding
Stage
Final
Change scope
Minor
Document ID
US12590130B2

Who this affects

Applies to
Drug manufacturers Healthcare providers Patients
Industry sector
3254 Pharmaceutical Manufacturing
Activity scope
Pharmaceutical Research Biotechnology IP
Geographic scope
United States US

Taxonomy

Primary area
Intellectual Property
Operational domain
Legal
Compliance frameworks
FDA 21 CFR Part 11
Topics
Healthcare Pharmaceuticals

Get alerts for this source

We'll email you when USPTO Patent Grants - Peptides (C07K) publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!